Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2025
Date Filed: March 14, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory filings rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary activity reported is the submission of an application for the quotation of securities.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference into Registration Statements on Form S-8 and Form F-3.
Exhibits: Exhibit 99.1 contains the "Application for quotation of securities - ATH".
Risks and Contingencies: The filing text does not provide specific details on risks, contingencies, or unusual items beyond the standard status of being a development stage enterprise.
Investor Verification Checklist
- Verify the status and outcome of the "Application for quotation of securities" referenced in Exhibit 99.1.
- Review the referenced Registration Statements (Form S-8 and Form F-3) for details on capital raising activities.
- Confirm the company's current cash runway and burn rate, as this filing does not contain financial statements.
- Monitor for subsequent filings regarding the listing or trading of the securities mentioned.